From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011 · see citing works

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · see citing works

Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)

Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works

2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetes—2018</i>

American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159 · see citing works

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,067 · see citing works

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · see citing works

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.

DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016 · see citing works

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · see citing works

Classification and Diagnosis of Diabetes

Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,356 · see citing works

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

Pathogenesis of NIDDM. A balanced overview.

DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085 · see citing works

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747 · see citing works

Bariatric Surgery and Long-term Cardiovascular Events

Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656 · see citing works

Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α

Itani, S. I., Ruderman, N. B., Schmieder, F., & Boden, G. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2005 · Cited by 1,390 · see citing works

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,260 · see citing works

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

Postic, C., & Girard, J. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,200 · see citing works

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,127 · see citing works

Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines

Makki, K., Froguel, P., & Wolowczuk, I. (2013) · ISRN Inflammation · doi:10.1155/2013/139239 · Cited by 1,085 · see citing works

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease

Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · see citing works

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study

(2015) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029 · see citing works

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial

Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Incretin hormones: Their role in health and disease

Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · see citing works

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 917 · see citing works

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 889 · see citing works

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 2× · see citing works

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · see citing works

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 861 · see citing works

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial

Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850 · see citing works

Obesity, insulin resistance and free fatty acids

Boden, G. (2011) · Current Opinion in Endocrinology, Diabetes &amp; Obesity · doi:10.1097/med.0b013e3283444b09 · Cited by 848 · see citing works

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease

Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R. A., Bugianesi, E., & Gastaldelli, A. (2013) · Nutrients · doi:10.3390/nu5051544 · Cited by 824 · see citing works

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

Lyssenko, V., Lupi, R., Marchetti, P., Guerra, S. D., Orho‐Melander, M., Almgren, P., Sjögren, M., Ling, C., Eriksson, K., Lethagen, Υ.-L., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30706 · Cited by 821 · see citing works

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial

Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790 · see citing works

PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD

Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778 · see citing works

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770 · see citing works

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · see citing works

Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial

Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674 · see citing works

Excessive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease

Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672 · see citing works

Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)

Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis

Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 634 · see citing works

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects

Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629 · see citing works

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

Aronoff, S., Rosenblatt, S., Braithwaite, S. S., Egan, J. W., Mathisen, A. L., & Schneider, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 626 · see citing works

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · see citing works

A Ceramide-Centric View of Insulin Resistance

Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 620 · see citing works

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

Korenblat, K. M., Fabbrini, E., Mohammed, B. S., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.075 · Cited by 592 · see citing works

Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance

Lotta, L. A., Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., Sharp, S. J., Luan, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 587 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

Impaired Glucose Tolerance as a Disorder of Insulin Action

Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578 · see citing works

Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans

Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575 · see citing works

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease

Khan, R. S., Bril, F., Cusi, K. J., & Newsome, P. N. (2018) · Hepatology · doi:10.1002/hep.30429 · Cited by 543 · see citing works

β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis

Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · see citing works

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · see citing works

The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis

Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 531 · see citing works

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes

Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518 · see citing works

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

Harnois, D. M. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505 · see citing works

A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes

Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503 · see citing works

Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 500 · see citing works

Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis

Chen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.019 · Cited by 491 · see citing works

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 460 · see citing works

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · see citing works

Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery

Taylor, R., Al-Mrabeh, A., Zhyzhneuskaya, S., Peters, C., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.003 · Cited by 450 · see citing works

Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars

Luukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428 · see citing works

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis

Marra, F., Gastaldelli, A., Svegliati‐Baroni, G., Tell, G., & Tiribelli, C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.003 · Cited by 425 · see citing works

Genetic control of de novo lipogenesis: role in diet-induced obesity

Strable, M. S., & Ntambi, J. M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409231003667500 · Cited by 415 · see citing works

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · see citing works

Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling

Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · see citing works

Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci

Stender, S., Kozlitina, J., Nordestgaard, B. G., Tybjærg‐Hansen, A., Hobbs, H. H., & Cohen, J. C. (2017) · Nature Genetics · doi:10.1038/ng.3855 · Cited by 401 · see citing works

Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension Trial

Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Naour, G. L., Hartemann–Heurtier, A., Bruckert, É., & Poynard, T. (2009) · Hepatology · doi:10.1002/hep.23270 · Cited by 363 · see citing works

Predictors of and Longitudinal Changes in Insulin Sensitivity and Secretion Preceding Onset of Type 2 Diabetes

Lyssenko, V., Almgren, P., Anevski, D., Perfekt, R., Lahti, K., Nissén, M., Isomaa, B., Forsen, B., Homström, N., Saloranta, C., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.1.166 · Cited by 361 · see citing works

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice

Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · see citing works

Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the san antonio metabolism study

Gastaldelli, A., Gaggini, M., & DeFronzo, R. A. (2017) · Diabetes · doi:10.2337/db16-1167 · Cited by 344 · see citing works

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338 · see citing works

The genetics of NAFLD

Anstee, Q. M., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.182 · Cited by 328 · see citing works

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328 · see citing works

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

Cui, J. Y., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 327 · see citing works

Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies

Sunny, N. E., Bril, F., & Cusi, K. J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.006 · Cited by 321 · see citing works

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320 · see citing works

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works

Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene

Kantartzis, K., Peter, A., Machicao, F. E., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 299 · see citing works

Fatty liver and lipotoxicity

Trauner, M., Arrese, M. A., & Wagner, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.007 · Cited by 291 · see citing works

Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease

Bril, F., Barb, D., Portillo-Sánchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. J. (2016) · Hepatology · doi:10.1002/hep.28985 · Cited by 291 · see citing works

NF-κB Activation, Rather Than TNF, Mediates Hepatic Inflammation in a Murine Dietary Model of Steatohepatitis

Peňa, A. D., Leclercq, I. A., Field, J., George, J., Jones, B., & Farrell, G. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.004 · Cited by 288 · see citing works

Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial

Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 280 · see citing works

PPARs and nonalcoholic fatty liver disease

Liss, K. H. H., & Finck, B. N. (2016) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275 · see citing works

GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy

Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · see citing works

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260 · see citing works

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · see citing works

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

Kotronen, A., Seppänen‐Laakso, T., Westerbacka, J., Kiviluoto, T. A., Arola, J. T., Ruskeepää, A., Orešič, M., & Yki‐Järvinen, H. (2008) · Diabetes · doi:10.2337/db08-1074 · Cited by 247 · see citing works

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246 · see citing works

Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle

Brehm, A., Krssak, M., Schmid, A. I., Nowotny, P., Waldhäusl, W., & Roden, M. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-1286 · Cited by 239 · see citing works

Dose-Response Effect of Pioglitazone on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.517 · Cited by 236 · see citing works

Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

van der Meer, R. W., Rijzewijk, L. J., de Jong, H. W. A. M., Lamb, H. J., Lubberink, M., Romijn, J. A., Bax, J. J., Roos, A., Otto Kamp, B., Paulus, W. J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.803916 · Cited by 234 · see citing works

Sweet Sixteenth for ChREBP: Established Roles and Future Goals

Abdul-Wahed, A., Guilmeau, S., & Postic, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.004 · Cited by 231 · see citing works

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · see citing works

Genetic Evidence for a Normal-Weight “Metabolically Obese” Phenotype Linking Insulin Resistance, Hypertension, Coronary Artery Disease, and Type 2 Diabetes

Yaghootkar, H., Scott, R. A., White, C. C., Zhang, W., Speliotes, E. K., Munroe, P. B., Ehret, G., Bis, J. C., Fox, C. S., Walker, M., et al. (2014) · Diabetes · doi:10.2337/db14-0318 · Cited by 218 · see citing works

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204 · see citing works

Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond

Grarup, N., Sandholt, C. H., Hansen, T. F., & Pedersen, O. B. (2014) · Diabetologia · doi:10.1007/s00125-014-3270-4 · Cited by 201 · see citing works

Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect

Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · see citing works

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199 · see citing works

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

Prato, S. D. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02847.x · Cited by 198 · see citing works

EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY

Rosenstock, J., EINHORN, D. F., Hershon, K. S., Glazer, N. B., & Yu, S. S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11251.x · Cited by 193 · see citing works

Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study

Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 192 · see citing works

The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population

Vaxillaire, M., Cavalcanti-Proença, C., Dechaume, A., Tichet, J., Marre, M., Balkau, B., Froguel, P., & for the DESIR Study Group (2008) · Diabetes · doi:10.2337/db07-1807 · Cited by 191 · see citing works

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits

Lupsa, B. C., & Inzucchi, S. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4663-6 · Cited by 191 · see citing works

Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes

Cusi, K. J., Sanyal, A. J., Zhang, S., Hartman, M. L., Bue‐Valleskey, J. M., Hoogwerf, B. J., & Haupt, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12973 · Cited by 188 · see citing works

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019

American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s004 · Cited by 183 · see citing works

Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in <scp>J</scp>apanese patients (<scp>LEAN</scp>‐<scp>J</scp>)

Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · see citing works

Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis

Bril, F., Lomonaco, R., Orsak, B., Ortiz‐Lopez, C., Webb, A., Tio, F. O., Hecht, J., & Cusi, K. J. (2013) · Hepatology · doi:10.1002/hep.26988 · Cited by 173 · see citing works

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

Sattar, N. A., FITCHETT, D. H., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 173 · see citing works

Metabolically normal obese people are protected from adverse effects following weight gain

Fabbrini, E., Yoshino, J., Yoshino, M., Magkos, F., Tiemann Luecking, C., Samovski, D., Fraterrigo, G., Okunade, A. L., Patterson, B. W., & Klein, S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78425 · Cited by 172 · see citing works

Metabolic stress in insulin's target cells leads to ROS accumulation – A hypothetical common pathway causing insulin resistance

Eriksson, J. W. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.06.044 · Cited by 165 · see citing works

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease

Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 165 · see citing works

Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss–induced decrease in liver fat in humans

Sevastianova, K., Kotronen, A., Gastaldelli, A., Perttilä, J., Hakkarainen, A., Lundbom, J., Suojanen, L.-U., Orho‐Melander, M., Lundbom, N. M. I., Ferrannini, E., et al. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012369 · Cited by 158 · see citing works

The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis

Bouthoorn, S. H., Valstar, G., Gohar, A., den Ruijter, H. M., Reitsma, J. B., Hoes, A. W., & Rutten, F. H. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118787415 · Cited by 158 · see citing works

Nonalcoholic Fatty Liver Disease

Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 152 · see citing works

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

JOY, T. R., McKenzie, C. A., Tirona, R. G., Summers, K. L., Seney, S. L., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152 · see citing works

Effect of Physiological Hyperinsulinemia on Gluconeogenesis in Nondiabetic Subjects and in Type 2 Diabetic Patients

Gastaldelli, A., Toschi, E., Pettiti, M., Frascerra, S., Quiñones-Galvan, A., Sironi, A. M., Natali, A., & Ferrannini, E. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1807 · Cited by 150 · see citing works

Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men

Suvitaival, T., Bondia‐Pons, I., Yetukuri, L., Pöhö, P., Nolan, J. J., Hyötyläinen, T., Kuusisto, J., & Orešič, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.014 · Cited by 147 · see citing works

Direct effect of GLP-1 infusion on endogenous glucose production in humans

Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143 · see citing works

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142 · see citing works

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · see citing works

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 141 · see citing works

The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 139 · see citing works

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · see citing works

Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus

Gastaldelli, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70015-8 · Cited by 138 · see citing works

GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway

He, Q., Sha, S., Sun, L., Zhang, J., & Dong, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.086 · Cited by 138 · see citing works

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133 · see citing works

Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it?

Nolan, C. J., & Larter, C. Z. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05823.x · Cited by 132 · see citing works

The safety of gliptins : updated data in 2018

Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 130 · see citing works

The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice

Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 129 · see citing works

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study

Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · see citing works

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 128 · see citing works

Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population

Ramya, K., Ayyappa, K. A., Ghosh, S., Mohan, V., & Radha, V. (2013) · Gene · doi:10.1016/j.gene.2013.09.012 · Cited by 127 · see citing works

Effect of Vildagliptin on Hepatic Steatosis

Macauley, M., Hollingsworth, K. G., Smith, F. E., Thelwall, P. E., Al-Mrabeh, A. H., Schweizer, A., Foley, J. E., & Taylor, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3794 · Cited by 126 · see citing works

Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus

Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A. (2011) · Hepatogastroenterology · doi:10.5754/hge11263 · Cited by 124 · see citing works

Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial

Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124 · see citing works

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia &amp; Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122 · see citing works

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study

Isokuortti, E., Zhou, Y., Peltonen, M., Bugianesi, E., Clement, K., Bonnefont-Rousselot, D., Lacorte, J.-M., Gastaldelli, A., Schuppan, D., Schattenberg, J. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4340-1 · Cited by 120 · see citing works

Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis

Gastaldelli, A., Miyazaki, Y., Pettiti, M., Buzzigoli, E., Mahankali, S., Ferrannini, E., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031941 · Cited by 117 · see citing works

Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease

Hyötyläinen, T., Jerby‐Arnon, L., Petäjä, E. M., Mattila, I. M., Jäntti, S. E., Auvinen, P., Gastaldelli, A., Yki‐Järvinen, H., Ruppin, E., & Orešič, M. (2016) · Nature Communications · doi:10.1038/ncomms9994 · Cited by 114 · see citing works

SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis

Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114 · see citing works

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial

Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113 · see citing works

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2

Zhou, Y., Llauradó, G., Orešič, M., Hyötyläinen, T., Orho‐Melander, M., & Yki‐Järvinen, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.010 · Cited by 112 · see citing works

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2317-z · Cited by 110 · see citing works

Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity

Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 110 · see citing works

Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes

Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Pichiri, I., Bertolini, L., Valbusa, F., Barbieri, E., Zoppini, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135329 · Cited by 103 · see citing works

Genomic aspects of NAFLD pathogenesis

Naik, A., Košir, R., & Rozman, D. (2013) · Genomics · doi:10.1016/j.ygeno.2013.03.007 · Cited by 101 · see citing works

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96 · see citing works

Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?

Gastaldelli, A. (2017) · Clinical Science · doi:10.1042/cs20170987 · Cited by 95 · see citing works

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the <scp>AWARD</scp> programme

Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89 · see citing works

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis

Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 88 · see citing works

Transcription factor 7–like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH #

Musso, G., Gambino, R., Pacini, G., Pagano, G., Durazzo, M., & Cassader, M. (2008) · Hepatology · doi:10.1002/hep.22659 · Cited by 87 · see citing works

Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

Junker, A. E., Gluud, L. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 86 · see citing works

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Seko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184767 · Cited by 80 · see citing works

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

Ohki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 79 · see citing works

Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease

Rosso, C., Mezzabotta, L., Gaggini, M., Salomone, F., Gambino, R., Marengo, A., Saba, F., Vanni, E., Younes, R., Saponaro, C., et al. (2015) · Hepatology · doi:10.1002/hep.28287 · Cited by 76 · see citing works

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

Aroor, A. R., Habibi, J., Ford, D. A., Nistala, R., Lastra, G., Manrique, C. M., Dunham, M. M., Ford, K. D., Thyfault, J. P., Parks, E. J., et al. (2015) · Diabetes · doi:10.2337/db14-0804 · Cited by 76 · see citing works

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects

Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76 · see citing works

The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes

Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., DeFronzo, R. A., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1159 · Cited by 75 · see citing works

A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression

Hwang, H.-J., Jung, T. W., Kim, B.-H., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.098 · Cited by 72 · see citing works

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial

Alam, S., Ghosh, J., Mustafa, G., Kamal, M. A., & Ahmad, N. (2018) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s158053 · Cited by 72 · see citing works

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., Sasaki, Y., Fukuda, H., Ohshige, T., Terashima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.008 · Cited by 71 · see citing works

Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery

Taylor, R., Al-Mrabeh, A. H., Zhyzhneuskaya, S. V., Peters, C. A., Barnes, A. C., Aribisala, B. S., Hollingsworth, K. G., Mathers, J. C., Sattar, N. A., & Lean, M. E. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.010 · Cited by 71 · see citing works

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

Bi, Y., Zhang, B., Xu, W., Yang, H., Feng, W., Li, C., Tong, G., Li, M., Wang, X., Shen, S., et al. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0638-3 · Cited by 71 · see citing works

Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis

Jung, Y., Choi, Y., Jung, G., Seo, H.-Y., Kim, H., Jang, B. K., Kim, J., Lee, I., Kim, M. K., & Park, K. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.028 · Cited by 70 · see citing works

Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism

Musso, G., Cassader, M., Bo, S., Michieli, F. D., & Gambino, R. (2012) · Diabetes · doi:10.2337/db12-0858 · Cited by 70 · see citing works

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70 · see citing works

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non‐alcoholic steatohepatitis

Armstrong, M. J., Hazlehurst, J., Hull, D., Guo, K., Borrows, S., Yu, J., Gough, S. C. L., Newsome, P. N., & Tomlinson, J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12272 · Cited by 69 · see citing works

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats

Maiztegui, B., Borelli, M. I., Madrid, V., Zotto, H. H. D., Raschia, M. A., Francini, F., Massa, M. L., Flores, L. E., Rebolledo, O. R., & Gagliardino, J. J. (2010) · Clinical Science · doi:10.1042/cs20100372 · Cited by 67 · see citing works

Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease

Bechmann, L. P., Gastaldelli, A., Vetter, D., Patman, G., Pascoe, L. A., Hannivoort, R. A., Lee, U. E., Fiel, M. I., Muñoz, Ú., Ciociaro, D., et al. (2011) · Hepatology · doi:10.1002/hep.24793 · Cited by 66 · see citing works

Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis

Klein, T., Fujii, M., Sandel, J. P., Shibazaki, Y., Wakamatsu, K., Mark, M., & Yoneyama, H. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0053-9 · Cited by 65 · see citing works

Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk

DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0520 · Cited by 65 · see citing works

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes

Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63 · see citing works

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

Fukuhara, T., Hyogo, H., Ochi, H., Fujino, H., Kan, H., Naeshiro, N., Honda, Y., Miyaki, D., Kawaoka, T., Tsuge, M., et al. (2014) · PubMed · Cited by 63 · see citing works

Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59 · see citing works

Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes

Brouwers, B., Schrauwen-Hinderling, V. B., Jelenik, T., Gemmink, A., Havekes, B., Bruls, Y., Dahlmans, D., Roden, M., Hesselink, M. K. C., & Schrauwen, P. (2017) · Clinical Science · doi:10.1042/cs20170261 · Cited by 59 · see citing works

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

Ideta, T., Shirakami, Y., Miyazaki, T., Kochi, T., Sakai, H., Moriwaki, H., & Shimizu, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226156 · Cited by 58 · see citing works

Interaction between hormone-sensitive lipase and ChREBP in fat cells controls insulin sensitivity

Morigny, P., Houssier, M., Mairal, A., Ghilain, C., Mouisel, É., Benhamed, F., Masri, B., Recazens, E., Denechaud, P., Tavernier, G., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0007-6 · Cited by 57 · see citing works

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus

Portillo-Sánchez, P., & Cusi, K. J. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 56 · see citing works

Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes

Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56 · see citing works

Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway

Ao, N., Yang, J., Wang, X., & Du, J. (2016) · Hepatology Research · doi:10.1111/hepr.12551 · Cited by 56 · see citing works

Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

Cusi, K. J. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52 · see citing works

VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin

Bourgeois, C. S., Wiggins, D. K., Hems, R., & Gibbons, G. F. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.2.e208 · Cited by 50 · see citing works

SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes

BAJAJ, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50 · see citing works

Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis

Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 50 · see citing works

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects

Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50 · see citing works

The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice

Fukuda-Tsuru, S., Kakimoto, T., Utsumi, H., Kiuchi, S., & Ishii, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.030 · Cited by 48 · see citing works

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801 · see citing works

Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review

Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity &amp; Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776 · see citing works

Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis

Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology &amp; Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749 · see citing works

Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association

Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727 · see citing works

Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease

Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618 · see citing works

A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes

Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593 · see citing works

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology &amp; Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586 · see citing works

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease

Khan, R. S., Bril, F., Cusi, K. J., & Newsome, P. N. (2018) · Hepatology · doi:10.1002/hep.30429 · Cited by 543 · see citing works

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · see citing works

Metabolic syndrome

Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463 · see citing works

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451 · see citing works

Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment

Stefan, N., Yki‐Järvinen, H., & Neuschwander‐Tetri, B. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 450 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 396 · see citing works

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354 · see citing works

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · see citing works

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316 · see citing works

Current treatment of non‐alcoholic fatty liver disease

Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305 · see citing works

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286 · see citing works

Non-alcoholic fatty liver disease: A patient guideline

Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264 · see citing works

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight

Eslam, M., El‐Serag, H. B., Francque, S., Sarin, S. K., Wei, L., Bugianesi, E., & George, J. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00635-5 · Cited by 248 · see citing works

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615978 · Cited by 243 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K. J., Hilliard, M. E., Isaacs, D. M., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 233 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025

ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M. S., Balapattabi, K., Beverly, E. A., Early, K. B., Bruemmer, D., Cusi, K. J., Echouffo-Tcheugui, J. B., et al. (2024) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 222 · see citing works

A researcher’s guide to preclinical mouse NASH models

Gallage, S., Avila, J. E. B., Ramadori, P., Focaccia, E., Rahbari, M., Ali, A., Malek, N. P., Anstee, Q. M., & Heikenwälder, M. F. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00700-y · Cited by 198 · see citing works

Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism

Xiao, H., Sun, X., Lin, Z., Yang, Y., Zhang, M., Xu, Z., Liu, P., Liu, Z., & Huang, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.023 · Cited by 197 · see citing works

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 193 · see citing works

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update

Barchetta, I., Cimini, F. A., & Cavallo, M. G. (2020) · Nutrients · doi:10.3390/nu12113302 · Cited by 188 · see citing works

Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

Govaere, O., Petersen, S. K., Martinez-Lopez, N., Wouters, J., Haele, M. V., Mancina, R., Jamialahmadi, O., Bilkei-Gorzo, O., Lassen, P. B., Darlay, R., et al. (2020) · bioRxiv · doi:10.1016/j.jhep.2021.12.012 · Cited by 158 · see citing works

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Chavez, C. P., Cusi, K. J., & Kadiyala, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 163 · see citing works

Metabolic liver disease in diabetes – From mechanisms to clinical trials

Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 160 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024

ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 167 · see citing works

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease

Barb, D., Repetto, E., Stokes, M. E., Shankar, S. S., & Cusi, K. J. (2021) · Obesity · doi:10.1002/oby.23263 · Cited by 148 · see citing works

Therapeutic management of metabolic dysfunction associated steatotic liver disease

Zeng, J., Fan, J., & Francque, S. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12525 · Cited by 131 · see citing works

Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications

Byrne, C. D., & Targher, G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14484 · Cited by 122 · see citing works

Preparing for the NASH Epidemic: A Call to Action

Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.074 · Cited by 122 · see citing works

Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care

Nogueira, J. P., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 126 · see citing works

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

Tomah, S., Alkhouri, N., & Hamdy, O. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00097-1 · Cited by 117 · see citing works

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

Jara, M., Norlin, J., Kjær, M. S., Almholt, K., Bendtsen, K. M., Bugianesi, E., Cusi, K. J., Galsgaard, E. D., Geybels, M. S., Gluud, L. L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03799-0 · Cited by 108 · see citing works

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100 · see citing works

Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)

Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96 · see citing works

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 97 · see citing works

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)

Ghosal, S., Datta, D., & Sinha, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-01663-y · Cited by 93 · see citing works

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis

Chakravarthy, M. V., Siddiqui, M. S., Forsgren, M. F., & Sanyal, A. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592373 · Cited by 89 · see citing works

Targeting Mitochondria in Diabetes

Jakovljevic, N. K., Pavlović, K., Jotić, A., Lalic, K. S., Stoiljkovic, M. M., Lukić, L., Milicic, T. J., Macesic, M. V., Gajović, J. S., & Lalic, N. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126642 · Cited by 90 · see citing works

The metabolic basis of nonalcoholic steatohepatitis

Chakravarthy, M. V., & Neuschwander‐Tetri, B. A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.112 · Cited by 87 · see citing works

Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84 · see citing works

Diabetes and cirrhosis: Current concepts on diagnosis and management

Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 87 · see citing works

Management of NAFLD in primary care settings

Wong, V. W., Zelber‐Sagi, S., Cusi, K. J., Carrieri, P., Wright, E. E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 82 · see citing works

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 81 · see citing works

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

Francque, S., Bédossa, P., Abdelmalek, M. F., Anstee, Q. M., Bugianesi, E., Ratziu, V., Huot-Marchand, P., Bruno, S., Junien, J., Broqua, P., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106170 · Cited by 78 · see citing works

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study

Cusi, K. J., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou‐Bozec, S., Bolze, S., Grouin, J., Megnien, S. J., Dubourg, J., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 78 · see citing works

Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis

Sehgal, R., Ilha, M., Vaittinen, M., Kamińska, D., Männistö, V., Kärjä, V. J., Tuomainen, M. H., Hanhineva, K., Romeo, S., Pajukanta, P., et al. (2021) · Nutrients · doi:10.3390/nu13103509 · Cited by 77 · see citing works

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes

Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.17925 · Cited by 77 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

Insulin Clearance in Health and Disease

Najjar, S. M., Caprio, S., & Gastaldelli, A. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031622-043133 · Cited by 77 · see citing works

Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies

Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74 · see citing works

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

Cooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 70 · see citing works

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 86 · see citing works

Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts

Eng, P. C., Forlano, R., Tan, T., Manousou, P., Dhillo, W. S., & Izzi‐Engbeaya, C. N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100835 · Cited by 72 · see citing works

Autoimmune responses and inflammation in type 2 diabetes

Prasad, M., Chen, E. W., Toh, S.-A. E. S., & Gascoigne, N. R. J. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0220-243r · Cited by 65 · see citing works

Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD

Kalavalapalli, S., Leiva, E. G., Lomonaco, R., Chi, X., Shrestha, S., Dillard, R., Budd, J., Romero, J. P., Li, C., Bril, F., et al. (2023) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/clinem/dgac660 · Cited by 64 · see citing works

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology &amp; Hepatology · doi:10.1016/s2468-1253(23)00270-4 · Cited by 63 · see citing works

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Chandran, V. I., Wernberg, C. W., Lauridsen, M. M., Skytthe, M. K., Bendixen, S. M., Larsen, F. T., Hansen, C. D., Grønkjær, L. L., Siersbæk, M. S., Caterino, T. D., et al. (2022) · Hepatology · doi:10.1002/hep.32620 · Cited by 63 · see citing works

The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials

Jalali, M., Rahimlou, M., Mahmoodi, M., Moosavian, S. P., Symonds, M. E., Jalali, R., Zare, M., Imanieh, M. H., & Stasi, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104799 · Cited by 63 · see citing works

Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death

Frietze, K. K., Brown, A., Das, D., Franks, R. G., Cunningham, J. L., Hayward, M. D., & Nickels, J. T. (2021) · Autophagy · doi:10.1080/15548627.2021.1920818 · Cited by 62 · see citing works

Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?

Budd, J. T., & Cusi, K. J. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.01.007 · Cited by 61 · see citing works

Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non‐alcoholic steatohepatitis

Guerra, S., Mocciaro, G., & Gastaldelli, A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13695 · Cited by 61 · see citing works

Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway

Ahmed, E. S. A., Mohamed, H. E., & Farrag, M. A. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221137435 · Cited by 59 · see citing works

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 61 · see citing works

The therapeutic landscape of hepatocellular carcinoma

Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 57 · see citing works

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH

Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56 · see citing works

Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases

Dewidar, B., Mastrototaro, L., Englisch, C., Ress, C., Granata, C., Rohbeck, E., Pesta, D. H., Heilmann, G., Wolkersdorfer, M. F., Esposito, I., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104714 · Cited by 56 · see citing works

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis

Singh, A., Sohal, A., & Batta, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i48.5205 · Cited by 52 · see citing works

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

Fouqueray, P., Bolze, S., Dubourg, J., Hallakou‐Bozec, S., Theurey, P., Grouin, J., Chevalier, C., Dagorn, P. G., Moller, D. E., & Cusi, K. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100474 · Cited by 52 · see citing works

A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

Cusi, K. J. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 52 · see citing works

Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials

Jin, Z., Yuan, Y., Chen, Z., Liu, S., & Weng, H. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108558 · Cited by 49 · see citing works

A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis

Dennis, A., Mouchti, S., Kelly, M., Fallowfield, J. A., Hirschfield, G. M., Pavlides, M., & Banerjee, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-71995-8 · Cited by 49 · see citing works

Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study

Cardoso, C. R. L., Villela‐Nogueira, C. A., Leite, N. C., & Salles, G. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01388-2 · Cited by 49 · see citing works

Tolerance assessment of dietary bile acids in common carp (Cyprinus carpio L.) fed a high plant protein diet

Yao, T., Gu, X., Liang, X., Fall, F. N., Cao, A., Zhang, S., Guan, Y., Sun, B., & Xue, M. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737012 · Cited by 47 · see citing works

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 51 · see citing works

Preparing for the NASH Epidemic: A Call to Action

Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 46 · see citing works

Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy

Mertens, J., Block, C. E. M. D., Spinhoven, M. J., Driessen, A. L. C., Francque, S., & Kwanten, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768576 · Cited by 46 · see citing works

Liver-targeting drugs and their effect on blood glucose and hepatic lipids

Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 46 · see citing works

NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook

Nascè, A., Gariani, K., Jornayvaz, F. R., & Szántó, I. (2022) · Antioxidants · doi:10.3390/antiox11061131 · Cited by 47 · see citing works

The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44 · see citing works

Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers

Basu, R., Noureddin, M., & Clark, J. M. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.005 · Cited by 44 · see citing works

Regulation of Cellular Senescence in Type 2 Diabetes Mellitus: From Mechanisms to Clinical Applications

Iwasaki, K., Abarca, C., & Aguayo‐Mazzucato, C. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0416 · Cited by 48 · see citing works

Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease

Soto‐Catalán, M., Opazo-Ríos, L., Quiceno, H., Lázaro, I., Moreno, J. A., Gómez‐Guerrero, C., Egido, J., & Mas, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052961 · Cited by 48 · see citing works

Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence

Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 50 · see citing works

Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease

Lambrecht, J., & Tacke, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.634409 · Cited by 44 · see citing works

Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy

Leith, D., Lin, Y., & Brennan, P. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.2 · Cited by 44 · see citing works

Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology

López, Y. O. N., Iliuk, A. B., Petrilli, A. M., Glass, C. E., Casu, A., & Pratley, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105779 · Cited by 44 · see citing works

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 43 · see citing works

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids

de Mello, V. D., Sehgal, R., Männistö, V., Klåvus, A., Nilsson, E., Perfilyev, A., Kamińska, D., Miao, Z., Pajukanta, P., Ling, C., et al. (2020) · Liver International · doi:10.1111/liv.14743 · Cited by 43 · see citing works

Preparing for the NASH epidemic: A call to action

Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 43 · see citing works

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 46 · see citing works

NAFLD in type 1 diabetes: overrated or underappreciated?

Mertens, J., Gaal, L. F. V., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211055557 · Cited by 44 · see citing works

Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease

Carranza-Trejo, A. M., Vetvicka, V., Vištejnová, L., Králíčková, M., & Montufar, E. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1887730 · Cited by 41 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?

Firneisz, G. (2014) · PubMed Central · doi:10.3748/wjg.v20.i27.9072 · Cited by 147 · see citing works

Steatosis and NASH in type 2 diabetes

Hu, M., Phan, F., Bourron, O., Ferré, P., & Foufelle, F. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.019 · Cited by 63 · see citing works

A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease

Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 20 · see citing works

Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease

Mihai, C., Mihai, B. M., & Prelipcean, C. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_14 · Cited by 1 · see citing works